NovaBay Pharmaceuticals Inc New (NBY) News

NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products...

NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that...

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses

Growth driven by efficient Avenova® direct-to-consumer e-marketing programs NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports...

NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results

Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova® physician dispensed and...

NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December...

NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023

DERMAdoctor sale reduces operating expenses and bolsters cash NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid &...

Form 8-K - Current report

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and...

Form D - Notice of Exempt Offering of Securities

Form 8-K - Current report

Form 8-K - Current report

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare...